Journal of Clinical Healthcare (JCHC) - page 26

20-24 24
Journal of Clinical Healthcare 3/2017
and/or Retroperitoneum. Revised 2012 (Resolution 29).
Dostęp: 21.06.2017. www.acr.org/guidelines.
11. Fuigham PF, Bishoff JT. Urinary tract imaging: basic princi-
ples. In: Dougal WS, Wein AJ, Kavoussi LR, Novick AC,
Partin AW, Peters CA et al. (ed.): Campwell-Walsh Urology.
Philadelphia ; Saunders Elsevier, 2013:99–139.
12. Jakubowski W. USG układu moczowo-płciowego. Ogólno-
pol Prz Med. 2008; 6: 46–48.
13. Sowińska-Neuman L. Umiejętność samodzielnego wyko-
nywania badań ultrasonograficznych w praktyce lekarza ro-
dzinnego. Ultrasonografia 2009; 9 (38): 51–54.
14. Jakubowski W. Diagnostyka ultrasonograficzna w choro-
bach nerek. Seria Wydawnicza „Praktyczna Ultrasonogra-
fia”. Warszawa – Zamość; Roztoczańska Szkoła Ultraso-
nografii, 2004.
15. Rouprêt M, Babjuk M, Compérat E, Zigeuner R, Sylvester
R, Burger M et al. Guidelines on Urothelial Carcinomas of
the Upper Urinary Tract. European Association of Urology,
Guidelines EAU 2013: 43–64 (1–22).
16. Borkowski A. Urologia. Warszawa; PZWL, 2006.
17. ACR Manual on Contrast Media, Wersja 9.0, American Col-
lege of Radiology Committee on Drugs and Contrast Media,
2013. Dostęp: 17.04.2017. http:// www.acr.org/~/ media/
ACR/Documents/PDF/QualitySafety/Resources/Contrast%2
0 Manual/2013_Contrast_Media.pdf
18. Mathers SA, Chesson RA, Proctor JM, McKenzie GA, Rob-
ertson E. The use of patient-centered outcome measures in
radiology: a systematic review. Acad Radiol 2006; 13:
1394–1404.
19. Palkowitsch P, Lengsfeld P, Stauch K, Heinsohn C, Kwon
ST, Zhang S. et al. Safety and diagnostic image quality of
Iopromide: results of a large non-interventional observa-
tional study of European and Asian patients (IMAGE). Acta
Radiol 2012; 53: 179–186.
20. Baerlocher MO, Asch M, Myers A. The use of contrast me-
dia. CMAJ 2010; 182(7): 697.
21. Malvinder S Parmar. Kidney stones. BMJ 2004; 328: 1420–
1424.
22. Frassetto L, Kohlstadt I. Treatment and prevention of kidney
stones: an update. Am Fam Physician 2011; 84: 1234–
1242.
23. Amin MB. Histological variants of urothelial carcinoma: di-
agnostic, therapeutic and prognostic implications. Modern
Pathol 2009; 22: S96–S118.
24. Stenzl A, Cowan NC, De Santis M, Kuczyk MA, Merseburg-
er AS, Ribal MJ et al.: Treatment of muscle-invasive and
metastatic bladder cancer: update of the EAU guidelines.
Eur Urol 2011; 59: 1009–1018.
25. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Bohle
A, Palou J, et al. Guidelines on non-muscle-invasive blad-
der cancer. Eur Urol 2011; 59: 584-594.
26. Chalasani V, Chin JL, Izawa JI. Histologic variants of
urothelial bladder cancer and nonurothelial histology in
bladder cancer. Can Urol Assoc J 2009; 3:193-198.
27. Reuter VE. The pathology of bladder cancer. Urology. 2006;
67: 11-17.
28. Gouda I, Mokhtar N, Bilal D, El-Bolkainy T, El-Bolkainy NM.
Bilharziasis and bladder cancer: a time trend analysis of
9843 patients. J Egypt Natl Canc Inst 2007; 19: 158-162.
29. Kirkali Z, Chan T, Manoharan M, Algaba F, Busch C, Cheng
L, et al. Bladder cancer: epidemiology, staging and grading,
and diagnosis. Urology 2005; 66:4-34.
30. Reynard J, Brewster S, Biers S. Nowotwory urologiczne: hi-
stopatologia i biologia molekularna. W: Bar K (red.). Oks-
fordzki podręcznik urologii. Lublin; Wydawnictwo Czelej,
2011: 206-227.